RespireRx Pharmaceuticals Inc (RSPI)

[K-G]

Press Release Source: Cortex Pharmaceuticals, Inc.
Wednesday May 16, 8:31 am ET

Cortex's CEO to Present at the JMP Securities Research Conference and Cortex's COO to Present at the Neurotech Industry Investing & Partnering Conference

IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX: COR - News), Chairman, President and CEO, Roger G. Stoll, Ph.D., will speak at the 6th Annual JMP Securities Research Conference to be held at The Ritz-Carlton Hotel located at 600 Stockton Street in San Francisco, California. Dr. Stoll will speak at 3:30 pm PDT on May 21, 2007 in Salon II. The conference will feature over 217 small-cap companies across a broad spectrum of sectors, including technology, healthcare, financial services and consumer products.

Dr. Stoll will provide an update on the Company's progress on its two distinct classes of AMPAKINE® product candidates, termed high and low impact compounds. Cortex's most advanced low impact AMPAKINE product candidate is CX717, a Phase IIa novel treatment for ADHD with proof-of-concept in adult patients. Dr. Stoll will also report animal findings on the ability of selective high AMPAKINE compounds to restore deficits found in brain growth factors associated with a number of neurodegenerative diseases.

Dr. Mark Varney, Ph.D., Cortex's CSO & COO, will participate in the 2nd Annual Neurotech Industry Organization (NIO) Conference to be held at the Westin San Francisco Hotel from May 17-18, 2007. Dr. Varney will participate with three other neuroscience company executives in a panel discussion that will be moderated by Dr. Harry Tracy, Publisher, Neuroinvestment. The topic of discussion will be "Advances in Neuropsychiatry." The session will take place between 10:45 am and 12:00 noon PDT on Thursday, May 17, 2007.